AbbVie Buys Optionality on Kestrel’s Pan-KRAS Bet With a Warrant Deal
Kestrel doses first patient in pan-KRAS Phase 1 with AbbVie holding a warrant to acquire the company.
Category Voyager Articles
Scancell’s iSCIB1+ Hits 77% PFS at 20 Months in Melanoma, Lands Fast Track
Scancell's iSCIB1+ DNA vaccine hits 77% PFS at 20 months in melanoma SCOPE trial, lands FDA Fast Track.
Lighthouse Stacks $12M Series A Plus $49M NIH Grant to Retry the Gingipain Bet
Lighthouse Pharmaceuticals raises $12M plus $49.2M NIH grant to retest the gingipain hypothesis in Alzheimer's.
Lilly Bets on Profluent for Kilobase-Scale AI-Designed Gene Editing
Profluent licenses AI-designed kilobase-scale recombinases to Lilly, validating protein design platforms in pharma.
Microbiome Therapeutics Quietly Raise £19M and €30M on the Same Day
EnteroBiotix and mbiomics close back-to-back rounds, signaling microbiome therapeutics still have backers.
Crowdfunding Is Officially Cool In Biotech. George Church Is Doing It.
Rejuvenate Bio opens a Wefunder crowdfund, putting Church-backed gene therapy in retail reach.
Fathom Got $47M to Combine AI Quantum Chemistry With Drug Discovery
Fathom Therapeutics, formerly Atommap, raises $47M Series A led by Sutter Hill for AI-quantum protein dynamics platform.
Asgard’s AT-108 Is The Craziest Immunotherapy I’ve Ever Seen. No Joke.
Asgard Therapeutics reveals preclinical data for AT-108, a first-in-class in vivo cell reprogramming cancer immunotherapy.
Sail Biomedicines’ Throws Their In-Vivo CAR-T Into The Ring
Sail Biomedicines reports NHP data showing in vivo CAR-T B-cell depletion across blood, bone marrow, and lymph nodes.
Tenaya Brings Year-One TN-401 Data to ASGCT. Cardiac Gene Therapy Needs a Win.
Tenaya Therapeutics presents 1-year RIDGE-1 Phase 1b/2 data for TN-401 AAV9 gene therapy in PKP2-ARVC at ASGCT 2026.